NCT02805465

Brief Summary

This study is a multicenter, prospective, randomized cross-over study to compare His Bundle Pacing (HBP) with Bi-Ventricular Pacing (BiVP) in HF Patients with AF who need atrial-ventricular node ablation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable heart-failure

Timeline
Completed

Started Jan 2016

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 30, 2016

Completed
21 days until next milestone

First Posted

Study publicly available on registry

June 20, 2016

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

June 20, 2016

Status Verified

June 1, 2016

Enrollment Period

2.5 years

First QC Date

May 30, 2016

Last Update Submit

June 15, 2016

Conditions

Keywords

Heart FailureAtrial FibrillationCRTBiVPHBP

Outcome Measures

Primary Outcomes (1)

  • Change of LVEF(%) from baseline in HBP and BiV Group

    18 months

Secondary Outcomes (10)

  • Change of 6min walking distance (m) from the baseline

    18 months

  • Change of LV end diastolic diameter(mm) from baseline

    18 months

  • Change of LV end systolic diameter(mm) from baseline

    18 months

  • The number of heart failure hospitalization after the procedure group

    18 months

  • Change of Quality of Life

    18 months

  • +5 more secondary outcomes

Study Arms (2)

HBP Group

EXPERIMENTAL

CRT Device and His-bundle Pacing. Patients will get His-bundle pacing through a CRT device first for 9 months then switch to Bi-ventricular pacing by the same CRT device for another 9 months.

Device: CRT Device and Bi-ventricular pacingDevice: CRT Device and His-bundle Pacing

BiVP Group

ACTIVE COMPARATOR

CRT Device and Bi-ventricular Pacing. Patients will get BiV pacing for 9 months through a CRT device then switch to His-bundle pacing by the same CRT device for another 9 months.

Device: CRT Device and Bi-ventricular pacingDevice: CRT Device and His-bundle Pacing

Interventions

Bi-ventricular pacing by a CRT device

BiVP GroupHBP Group

His-bundle pacing by a CRT device through the pacing lead at His-bundle region

BiVP GroupHBP Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is at least 18 years old
  • Subject or authorized legal guardian or representative has signed and dated the Informed
  • Subject is expected to remain available for follow-up visits at the study center
  • Subjects with heart failure NYHA Class II-IV
  • Subjects with LVEF no greater than 40%
  • Subjects with persistent atrial fibrillation or atrial flutter with uncontrolled ventricular rate

You may not qualify if:

  • Subjects with the width of ECG Q, R, S wave (QRS) complex \>120ms
  • Subjects with life expectancy less than 3 years
  • Subjects with mechanical right heart valve
  • Subjects with primary valvular disease
  • Subjects with heart transplant, or is currently on a heart transplant list
  • Subjects who are pregnant, or of childbearing potential and not on a reliable form of birth control
  • Subjects with significant renal dysfunction, as manifested by serum creatinine level \>2.5 mg/dl or ≥275 μmol/L or estimated glomerular filtration rate (GFR) ≤30 mL/min/1.72 m2, which is documented within the 30 days prior to enrollment or at baseline.
  • Subjects with significant hepatic dysfunction, as evidenced by a hepatic function panel (serum) \> 3 times upper limit of normal, which is documented within the 30 days prior to enrollment or at baseline.
  • Subjects with chronic or treatment-resistant severe anemia (hemoglobin \<10.0 g/dL), which is documented within the 30 days prior to enrollment or at baseline

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Affliated Hospital, Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China

RECRUITING

Related Publications (1)

  • Huang W, Wang S, Su L, Fu G, Su Y, Chen K, Zou J, Han H, Wu S, Sheng X, Chen X, Fan X, Xu L, Zhou X, Mao G, Ellenbogen KA, Whinnett ZI. His-bundle pacing vs biventricular pacing following atrioventricular nodal ablation in patients with atrial fibrillation and reduced ejection fraction: A multicenter, randomized, crossover study-The ALTERNATIVE-AF trial. Heart Rhythm. 2022 Dec;19(12):1948-1955. doi: 10.1016/j.hrthm.2022.07.009. Epub 2022 Jul 14.

MeSH Terms

Conditions

Heart FailureAtrial Fibrillation

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesArrhythmias, CardiacPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Weijian Huang, MD

    Wenzhou 1st Affliated Hopsital, Wenzhou Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dean of Cardiology, First Affiliated Hospital of Wenzhou Medical University

Study Record Dates

First Submitted

May 30, 2016

First Posted

June 20, 2016

Study Start

January 1, 2016

Primary Completion

July 1, 2018

Study Completion

July 1, 2018

Last Updated

June 20, 2016

Record last verified: 2016-06

Locations